Lymphoma Canada is conducting a survey and interviews of lymphoma patients with experience with romidepsin (Istodax) to appeal to the Canadian governments to provide funding for this treatment in Canada.
You don’t need to live in Canada to complete this survey or to participate in the interview.
Romidepsin (Istodax) has been approved by the FDA and Canadians are also trying to gain access to this new treatment.
If you or someone you know or love has had experience with romidepsin (Istodax), please reach out to us. We are preparing our submission for the pan-Canadian Oncology Drug Review (pCODR). If you are not familiar already, pCODR makes recommendations to the provinces and territories to help them decide whether they will provide funding for new cancer drugs. Understanding the experiences of patients and caregivers is a key element in the pCODR review process and pCODR allows patient groups to do this through “patient submissions”.
Your confidential input could mean the difference to provincial governments who will consider funding for this important new therapy. You DO NOT have to be Canadian to participate in this survey or an interview. Please consider calling us at 866-659-5556 or clicking through to the survey below.
The survey has been extended until midnight Pacific Time on Friday, December 5th and should take about 10 minutes of your time.
By completing this survey OR PARTICIPATING IN AN INTERVIEW, you are a part of the process that may heLp OTHER patients gain access to this new treatment in Canada.
Our lymphoma patients and their families thank you for your support!
You may access it by clicking on the appropriate link below:
Survey for Patients WITH romidepsin (Istodax) Experience
